Home » Stocks » INCY

Incyte Corporation (INCY)

Stock Price: $99.39 USD -1.11 (-1.10%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $99.40 +0.01 (0.01%) Jan 26, 4:45 PM
Market Cap 21.77B
Revenue (ttm) 2.46B
Net Income (ttm) -334.54M
Shares Out 218.78M
EPS (ttm) -1.55
PE Ratio n/a
Forward PE 27.10
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $99.39
Previous Close $100.50
Change ($) -1.11
Change (%) -1.10%
Day's Open 100.21
Day's Range 98.25 - 101.33
Day's Volume 930,809
52-Week Range 63.18 - 109.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 4 days ago

Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.

Business Wire - 5 days ago

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Squamous Cell Carcinoma of the Anal Canal (SCAC)

Business Wire - 1 week ago

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast for 8:00 a.m. E...

Accesswire - 2 weeks ago

PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced th...

Other stocks mentioned: MOR
Zacks Investment Research - 3 weeks ago

Incyte (INCY) enters into a collaboration with Cellenkos to evaluate the combination of Jakafi and CK0804 in patients with myelofibrosis.

Benzinga - 3 weeks ago

Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B....

Other stocks mentioned: ALT, BCDA
Business Wire - 3 weeks ago

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804

Business Wire - 1 month ago

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

PRNewsWire - 1 month ago

INDIANAPOLIS, Dec. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published peer-reviewed res...

Other stocks mentioned: LLY
Business Wire - 1 month ago

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 39th Annual J. P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 7:30 a...

Business Wire - 1 month ago

WILMINGTON, Del. & PLANEGG/MUNICH, Germany--(BUSINESS WIRE)---- $INCY #ASH20--Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presen...

Business Wire - 1 month ago

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with r/r B-Cell Non-Hodgkin Lymphomas

Zacks Investment Research - 1 month ago

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Business Wire - 1 month ago

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH20--First Data from REACH3 Show Ruxolitinib (Jakafi) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent cGVHD

Seeking Alpha - 1 month ago

Back on Dec. 29, 2019, I published an article here on Seeking Alpha, "Incyte Corporation: Wait And Watch." Those who waited and watched would have been well rewarded, with significantly lower ...

Zacks Investment Research - 2 months ago

Lilly's (LLY) rheumatoid arthritis drug, Olumiant gets Emergency Use Authorization for treating hospitalized COVID-19 patients in combination with Gilead's Veklury.

Other stocks mentioned: LLY
PRNewsWire - 2 months ago

INDIANAPOLIS, Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) issued an Emergency Use...

Other stocks mentioned: LLY
GuruFocus - 2 months ago

The terms "Nasdaq" and "undervalued" do not go hand-in-hand in the minds of most investors. The high-profile tech and tech-adjacent stocks that make up the index are usually awarded eye-wateri...

Other stocks mentioned: BIDU, WBA
Zacks Investment Research - 2 months ago

Incyte (INCY), Xencor and MorphoSys ink deal to evaluate the combination of tafasitamab, plamotamab and lenalidomide in lymphoma indications.

Other stocks mentioned: MOR
Business Wire - 2 months ago

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, December 1, 2020 at 10:30 ...

Business Wire - 2 months ago

MONROVIA, Calif. & PLANEGG/MUNICH, Germany & WILMINGTON, Del.--(BUSINESS WIRE)--Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (N...

Other stocks mentioned: MOR, XNCR
Business Wire - 2 months ago

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cance...

Seeking Alpha - 2 months ago

Incyte Corporation (INCY) CEO Hervé Hoppenot on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Incyte (INCY) misses earnings and sales expectations in the third quarter. However, the company's lead drug, Jakafi, reports encouraging growth.

Investors Business Daily - 2 months ago

Incyte early Thursday posted earnings that fell well short of Wall Street expectations, and revenue that narrowly missed views, and INCY stock slipped early following a big jump Wednesday. The...

Zacks Investment Research - 2 months ago

Incyte (INCY) delivered earnings and revenue surprises of -68.06% and -0.99%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Business Wire - 2 months ago

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--More than 40 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual Meeting

Zacks Investment Research - 2 months ago

Incyte Corp (INCY) has been struggling lately, but the selling pressure may be coming to an end soon.

PRNewsWire - 2 months ago

INDIANAPOLIS, Nov. 2, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today positive data for Olumiant® (baricitinib) will be presented at ACR Conver...

Other stocks mentioned: LLY
Seeking Alpha - 2 months ago

CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkp...

Other stocks mentioned: CASI, OCUL, ZLAB
Business Wire - 2 months ago

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Ranked Second Among Science Magazine's 2020 Top Biopharma Employers

PRNewsWire - 2 months ago

INDIANAPOLIS, Oct. 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT®) will be presented at th...

Other stocks mentioned: LLY
Zacks Investment Research - 2 months ago

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 2 months ago

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2020 results.

Business Wire - 2 months ago

WILMINGTON, Del.--(BUSINESS WIRE)--Results from Incyte's Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported QoL Assessments.

Business Wire - 3 months ago

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Thursday, Nove...

Forbes - 3 months ago

Incyte Corp stock moved more than 10% in the last 5 trading days, while the S&P was up 3.7%. While the stock is overall up this year, it is still 10% below the year’s high.

Seeking Alpha - 3 months ago

10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million.

Other stocks mentioned: CRVS, TXG, ZLAB
PRNewsWire - 3 months ago

INDIANAPOLIS, Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) are sharing additional data showing baricitinib in combination with remdesivir reduced ti...

Other stocks mentioned: LLY
Business Wire - 3 months ago

MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics Inc. today announced the company has entered into a strategic collaboration with Incyte (NASDAQ: INCY) to discover first-in-class peptide th...

Seeking Alpha - 4 months ago

Baricitinib/Olumiant COVID-19 results a plus.

PRNewsWire - 4 months ago

INDIANAPOLIS, Sept. 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Produc...

Business Wire - 4 months ago

Analyst and investor conference call and webcast scheduled for Tuesday, September 29, 2020 at 9:00 a.m. EDT / 3:00 p.m. CEST

Other stocks mentioned: MOR
Zacks Investment Research - 4 months ago

M&A Activities Intensify in Pharma Industry.

Other stocks mentioned: GILD, IMMU, LLY, MRK, SGEN
Zacks Investment Research - 4 months ago

Merck, Gilead and Lilly make progress on an otherwise slow news day.

Other stocks mentioned: GILD, IMMU, LLY, MRK, SGEN
Investors Business Daily - 4 months ago

Eli Lilly and Incyte released positive initial data of their coronavirus treatment when combined with Gilead's remdesivir and said they would seek emergency use authorization from the FDA. The...

Other stocks mentioned: GILD, LLY
Market Watch - 4 months ago

Eli Lily & Co. LLY, +1.27% and Incyte Corp. INCY, -0.29% said Monday that their rheumatoid arthritis drug Olumiant helped reduce recovery time in hospitalized COVID-19 patients when it was use...

Other stocks mentioned: LLY
Forbes - 4 months ago

Not all biotechs are created equal. Strong balance sheets can separate the weak from the strong.

Other stocks mentioned: REGN, VERX
Business Wire - 4 months ago

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that Massachusetts General Cancer Center is the recipient of the first Incyte Ingenuity Award, an annual program that wa...

About INCY

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase I... [Read more...]

Industry
Biotechnology
IPO Date
Nov 4, 1993
CEO
Herve Hoppenot
Employees
1,456
Stock Exchange
NASDAQ
Ticker Symbol
INCY
Full Company Profile

Financial Performance

In 2019, Incyte's revenue was $2.16 billion, an increase of 14.71% compared to the previous year's $1.88 billion. Earnings were $446.91 million, an increase of 308.16%.

Financial Statements

Analyst Forecasts

According to 20 analysts, the average rating for Incyte stock is "Buy." The 12-month stock price forecast is 105.69, which is an increase of 6.34% from the latest price.

Price Target
$105.69
(6.34% upside)
Analyst Consensus: Buy